LSPG(SZ:301111)2025-01-17 13:21Financial Performance Expectations - The company expects a net profit attributable to shareholders of between 0.00 million and 5.00 million yuan, representing a decline of 85.08% to 100.00% compared to the previous year's profit of 3,350.17 million yuan[3]. - The expected net profit after deducting non-recurring gains and losses is projected to be a loss of 5.00 million to 10.00 million yuan, a decrease of 121.17% to 142.33% from the previous year's profit of 2,362.32 million yuan[3]. - The anticipated impact of non-recurring gains and losses on net profit is estimated to be approximately 10.00 million to 11.00 million yuan[6]. Reasons for Performance Decline - The decline in performance is attributed to increased expenses from the new healthcare business segment, acquisition-related costs, and a decrease in gross profit margin from the main business[5]. - The company has expanded its sales and new business teams, leading to increased personnel compensation expenses[5]. - Capital investments have increased, resulting in reduced amounts available for financial management and decreased financial returns due to lower market yields[5]. Future Outlook - The company is in the process of annual auditing, and the specific data for the 2024 fiscal year will be disclosed in the annual report[7]. - The company aims to enhance profitability and achieve sustainable and stable operations[7].